SCHEMBL20520318

SCHEMBL20520318

COc1ncccc1CCC(N)=O

nearest known ligand 0.54

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SLC13A5 Q86YT5 4/20 0.54
MTNR1A P48039 2/20 0.48
C3AR1 Q16581 1/20 0.43
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
KDM1A O60341 3/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
JAK2 O60674 1/20 0.38
JAK3 P52333 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21223989 0.86 SLC13A5 (0.56) SLC13A5MTNR1AC3AR1HTR2AHTR2C
SCHEMBL7499858 0.86 SLC13A5 (0.63) SLC13A5C3AR1KDM1AMAOAMAOB
SCHEMBL30488626 0.86 SLC13A5 (0.56) SLC13A5MTNR1AC3AR1HTR2AHTR2C
SCHEMBL8665005 0.84 SLC13A5 (0.54) SLC13A5C3AR1HTR2AHTR2CKDM1A
SCHEMBL10736337 0.81 CYP4F2 (0.56) SLC13A5C3AR1
SCHEMBL20520324 0.79 P2RX7 (0.47) MTNR1A
SCHEMBL3055288 0.78 TAAR1 (0.52) SLC13A5HTR2AHTR2CKDM1AMAOA
SCHEMBL5780541 0.78 SLC13A5 (0.54) SLC13A5C3AR1HTR2AHTR2CKDM1A
SCHEMBL28960253 0.78 SLC13A5 (0.48) SLC13A5KDM1AMAOAMAOBTDP1
SCHEMBL1734905 0.77 NPC1 (0.50) SLC13A5C3AR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174540-A1 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives GRUENENTHAL GMBH (DE) 2023-06-08 US disclosed
US-20210179627-A1 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives Grünenthal GmbH (DE) 2021-06-17 US disclosed
US-20200399280-A1 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives Grünenthal GmbH (DE) 2020-12-24 US disclosed
US-10807989-B2 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives Grünenthal GmbH (DE) 2020-10-20 US disclosed
US-20190106430-A1 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES Grünenthal GmbH (DE) 2019-04-11 US disclosed
US-20180282341-A1 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES GRUENENTHAL GMBH (DE) 2018-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106430-A1 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES OPRK1, OPRD1, PKD2 SLC13A5 3361/4885MTNR1A 419/4885C3AR1 1192/4885
US-20200399280-A1 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, PKD2 SLC13A5 3361/4885MTNR1A 419/4885C3AR1 1192/4885
US-20180282341-A1 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES OPRK1, OPRD1, PKD2 SLC13A5 3361/4885MTNR1A 419/4885C3AR1 1192/4885
US-10807989-B2 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives OPRK1, OPRD1, PKD2 SLC13A5 3361/4885MTNR1A 419/4885C3AR1 1192/4885
US-20210179627-A1 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, PKD2 SLC13A5 3361/4885MTNR1A 419/4885C3AR1 1192/4885
US-20230174540-A1 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives OPRK1, OPRD1, PKD2 SLC13A5 3361/4885MTNR1A 419/4885C3AR1 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.